Company news
Bright Minds Biosciences Inc. (CSE:DRUG) news
Bright Minds Biosciences Inc. news releases on 6ix. Latest, Sep 30, 2026: Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS…
Press releases & updates
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
September 30, 2026
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
May 26, 2026
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
January 9, 2026
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
January 6, 2026
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
January 6, 2026
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)
January 6, 2026
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
January 5, 2026
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
November 25, 2025
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
November 17, 2025
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
November 6, 2025
Bright Minds Biosciences to Present at Upcoming Conferences
October 30, 2025
Bright Minds Biosciences to Present at Upcoming Conferences
October 30, 2025
BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING
September 4, 2025
Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
September 4, 2025
Bright Minds Biosciences to Present at Upcoming Conferences
August 25, 2025
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
May 28, 2025
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
May 20, 2025
Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101
May 13, 2025
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
April 28, 2025
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
March 4, 2025
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
February 24, 2025
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
January 7, 2025
Bright Minds Biosciences : Annual Report for Fiscal Year Ending September 30, 2024 (Form 20-F)
December 31, 2024
Bright Minds is Unaware of Any Material Changes
October 14, 2024
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
September 12, 2024
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
December 6, 2023
CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)
July 12, 2023
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing
October 18, 2021
Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th
October 7, 2021